34 results on '"Jager, Agnes"'
Search Results
2. Clinical decision support systems for multidisciplinary team decision-making in patients with solid cancer: Composition of an implementation model based on a scoping review
- Author
-
Hendriks, Mathijs P., Jager, Agnes, Ebben, Kees C.W.J., van Til, Janine A., and Siesling, Sabine
- Published
- 2024
- Full Text
- View/download PDF
3. Development and validation of an UPLC–MS/MS method for the quantification of tamoxifen and its main metabolites in human scalp hair
- Author
-
Drooger, Jan C., Jager, Agnes, Lam, Mei-Ho, den Boer, Mathilda D., Sleijfer, Stefan, Mathijssen, Ron H.J., and de Bruijn, Peter
- Published
- 2015
- Full Text
- View/download PDF
4. Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study.
- Author
-
Akdeniz, Delal, van Barele, Mark, Heemskerk-Gerritsen, Bernadette A.M., Steyerberg, Ewout W., Hauptmann, Michael, van de Beek, Irma, van Engelen, Klaartje, Wevers, Marijke R., Gómez García, Encarnacion B., Ausems, Margreet G.E.M., Berger, Lieke P.V., van Asperen, Christi J., Adank, Muriel A., Collée, Margriet J., Stommel-Jenner, Denise J., Jager, Agnes, Schmidt, Marjanka K., and Hooning, Maartje J.
- Subjects
BRCA genes ,BREAST cancer ,DISEASE risk factors ,NEOADJUVANT chemotherapy ,ADJUVANT chemotherapy - Abstract
BRCA1/2 mutation carriers with primary breast cancer (PBC) are at high risk of contralateral breast cancer (CBC). In a nationwide cohort, we investigated the effects of chemotherapeutic agents given for PBC on CBC risk separately in BRCA1 and BRCA2 mutation carriers. BRCA1 or BRCA2 mutation carriers with an invasive PBC diagnosis from 1990 to 2017 were selected from a Dutch cohort. We estimated cumulative CBC incidence using competing risks analysis. Hazard ratios (HR) for the effect of neo-adjuvant or adjuvant chemotherapy and different chemotherapeutic agents on CBC risk were estimated using Cox regression. We included 1090 BRCA1 and 568 BRCA2 mutation carriers; median follow-up was 8.9 and 8.4 years, respectively. Ten-year cumulative CBC incidence for treatment with and without chemotherapy was 6.7% [95%CI: 5.1–8.6] and 16.7% [95%CI: 10.8–23.7] in BRCA1 and 4.8% [95%CI: 2.7–7.8] and 16.0% [95%CI: 9.3–24.4] in BRCA2 mutation carriers, respectively. Chemotherapy was associated with reduced CBC risk in BRCA1 (multivariable HR: 0.46, 95%CI: 0.29–0.74); a similar trend was observed in BRCA2 mutation carriers (HR: 0.63, 95%CI: 0.29–1.39). In BRCA1 , risk reduction was most pronounced in the first 5 years (HR: 0.32, 95%CI: 0.17–0.61). Anthracyclines and the combination of anthracyclines with taxanes were associated with substantial CBC risk reduction in BRCA1 carriers (HR: 0.34, 95%CI: 0.17–0.68 and HR: 0.22, 95%CI: 0.08–0.62, respectively). Risk-reducing effects of chemotherapy are substantial for at least 5 years and may be used in personalised CBC risk prediction in any case for BRCA1 mutation carriers. • Contralateral breast cancer (CBC) risk is high in BRCA1/2 mutation carriers. • Chemotherapy for primary breast cancer results in decreased CBC risk in BRCA1. • Anthracyclines with/without taxanes show the largest CBC risk reduction in BRCA1. • For BRCA2 similar trends are observed as in BRCA1 mutation carriers. • Chemotherapy must be considered in personalised CBC risk models. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
5. The impact of menstruation persistence or recovery after chemotherapy on survival in young patients with hormone receptor negative breast cancer.
- Author
-
van Barele, Mark, Heemskerk-Gerritsen, Bernadette A.M., van Doorn, Helena C., Schmidt, Marjanka K., Hooning, Maartje J., and Jager, Agnes
- Subjects
HORMONE receptors ,MENSTRUATION ,HORMONE receptor positive breast cancer ,PROPORTIONAL hazards models ,POSTMENOPAUSE ,BREAST cancer - Abstract
Hormone replacement therapy can diminish hormone depletion-related complaints in postmenopausal women, but is contraindicated for postmenopausal breast cancer (BC) patients. Recovery of menstruation after chemotherapy-induced amenorrhea in young hormone receptor-negative BC patients however, is accepted. To determine the safety of this strategy, we investigated the effect of recovery of menstruation on disease-free survival (DFS) and overall survival (OS) in young hormone receptor-negative BC patients treated with (neo)adjuvant chemotherapy. We selected 636 patients from a single-center cohort with early stage hormone receptor-negative BC and under the age of 50 years when treated with chemotherapy. Sufficient data on course of menstruation in medical records was retrospectively found for 397 patients, of whom 299 patients (75%) had a recovery of menstruation after chemotherapy. We used Cox proportional hazards models to estimate hazard ratios (HR) for the effect of recovery of menstruation on DFS and OS. Patients with recovery of menstruation after chemotherapy less frequently had lymph node involvement at diagnosis (45% vs 66%, p = 0.001). After a median follow-up of 6.7 years, the adjusted hazard ratios were 1.45 (95% CI: 0.83–2.54) for DFS and 1.19 (95% CI: 0.71–1.98) for OS. No significantly increased recurrence risk was found for hormone receptor-negative BC patients with recovery of menstruation after chemotherapy. However, the outcome of the multivariable model is not reassuring and a potentially increased recurrence risk cannot be excluded. The results need to be validated in a larger prospective study for a more definitive answer. • Menstruation often recovers after chemotherapy in young breast cancer patients. • This is currently accepted for those with a hormone receptor negative subtype. • The cell type such tumors arise from is possibly sensitive to paracrine stimulation. • Recovery of menstruation may still negatively affect outcome in these patients. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
6. Hospital-based or home-based administration of oncology drugs? A micro-costing study comparing healthcare and societal costs of hospital-based and home-based subcutaneous administration of trastuzumab.
- Author
-
Franken, Margreet, Kanters, Tim, Coenen, Jules, de Jong, Paul, Jager, Agnes, and Groot, Carin Uyl-de
- Subjects
MEDICAL care costs ,DRUG administration ,CAREGIVERS ,MEDICAL personnel ,METASTATIC breast cancer - Abstract
To investigate resource use and time investments of healthcare professionals, patients and their family and to compare healthcare and societal costs of one single hospital-based and one single home-based subcutaneous administration of trastuzumab in The Netherlands. We conducted a bottom-up micro-costing study. Patients diagnosed with HER2+ early or metastatic breast cancer were recruited in four Dutch hospitals. For healthcare costs, data were collected on drug use, consumables, use of healthcare facilities, time of healthcare professionals, and travelling distance of the nurse. For societal costs, data were collected on patient and family costs (including travelling expenses and time of informal caregivers) and productivity losses of paid and unpaid work. Societal costs of one single administration of SC trastuzumab were €1753 within the home-based and €1724 within the hospital-based setting. Drug costs of trastuzumab were identical in both settings (€1651). Healthcare costs were higher for home-based administration (€91 versus €47) mainly because of more time of healthcare professionals (110 versus 38 minutes). Costs for patient and family were, however, lower for home-based administration due to travelling expenses (€7 versus €0) and time of informal caregivers (€14 versus €4). Costs for productivity losses were similar for both settings. Home-based subcutaneous administration of trastuzumab is more time consuming for healthcare professionals and therefore more costly than hospital-based administration. The total budget impact can be large considering that a large number of patients receive a large number of cycles of oncology treatments. If home-based administration is the way forward, novel approaches are crucial for ensuring efficiency of home-based care. • Home-based administration of SC trastuzumab almost triples the time of healthcare professionals. • Healthcare costs are almost twice as much for home-based than for hospital-based administration. • Patient and family costs are almost five times lower for home-based than for hospital-based administration. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
7. Cardiac monitoring in HER2-positive patients on trastuzumab treatment: A review and implications for clinical practice.
- Author
-
Bouwer, Nathalie I., Jager, Agnes, Liesting, Crista, Kofflard, Marcel J.M., Brugts, Jasper J., Kitzen, Jos J.E.M., Boersma, Eric, and Levin, Mark-David
- Subjects
ECHOCARDIOGRAPHY ,EPIDERMAL growth factor receptors ,PATIENT monitoring ,VENTRICULAR ejection fraction - Abstract
Trastuzumab prolongs progression-free and overall survival in patients with human epidermal growth factor receptor 2 (HER2) positive breast cancer. However, trastuzumab treatment is hampered by cardiotoxicity, defined as a left ventricular ejection fraction (LVEF) decline with a reported incidence ranging from 3 to 27% depending on variable factors. Early identification of patients at increased risk of trastuzumab-induced myocardial damage is of great importance to prevent deterioration to irreversible cardiotoxicity. Although current cardiac monitoring with multi gated acquisition (MUGA) scanning and/or conventional 2D-echocardiography (2DE) have a high availability, their reproducibility are modest, and more sensitive and reliable techniques are needed such as 3D-echocardiography (3DE) and speckle tracking echocardiography (STE). But which other diagnostic imaging modalities are available for patients before and during trastuzumab treatment? In addition, what is the optimal frequency and duration of cardiac monitoring? At last, which biomarker monitoring strategies are currently available for the identification of cardiotoxicity in patients treated with trastuzumab? • Current MUGA is not sensitive and reliable enough to detect cardiotoxicity early. • 3DE (with STE) is most suitable for cardiac monitoring of patients on trastuzumab. • The optimal frequency and duration of cardiac monitoring is not yet established. • MPO and hs-troponin are promising biomarkers to detect cardiotoxicity. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
8. Whole exome sequencing of cell-free DNA - A systematic review and Bayesian individual patient data meta-analysis.
- Author
-
Bos, Manouk K., Angus, Lindsay, Nasserinejad, Kazem, Jager, Agnes, Jansen, Maurice P. H. M., Martens, John W. M., and Sleijfer, Stefan
- Abstract
Molecular profiling of tumor derived cell free DNA (cfDNA) is gaining ground as a prognostic and predictive biomarker. However to what extent cfDNA reflects the full metastatic landscape as currently determined by tumor tissue analysis remains controversial. Though technically challenging, whole exome sequencing (WES) of cfDNA enables thorough evaluation of somatic alterations. Here, we review the feasibility of WES of cfDNA and determine the sensitivity of WES-detected single nucleotide variants (SNVs) in cfDNA on individual patient data level using paired tumor tissue as reference x 100%). The pooled sensitivity was 50% (95% credible interval (Cl): 29-72%). The tissue mutant allele frequency (MAF) of variants exclusively identified in tissue was significantly lower (12.5%, range: 0.5-18%) than the tissue MAF of variants identified in both tissue and cfDNA (23.9%, range: 17-38%), p = 0.004. The overall agreement (* "1"J™ x 100%)between SNVs in cfDNA and tumor tissue was 31% (95% Cl: 15-49%). The number of detected SNVs was positively correlated with circulating tumor DNA (ctDNA) fraction (p = 0.015). A sub analysis of samples with ctDNA fractions a 25% improved the sensitivity to 69% (95% Cl: 46-89%) and agreement to 46% (95% Cl: 36-59%), suggesting that WES is mainly feasible for patients with high ctDNA fractions. Pre- and post-analytical procedures were highly variable between studies rendering comparisons problematic. In conclusion, various aspects of WES of cfDNA are largely in its investigative phase, standardization of methodologies is highly needed to bring this promising technique to its clinical potential. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
9. Exploring the Psychosocial Needs of Adolescents Whose Parent Is Diagnosed With Breast Cancer.
- Author
-
Hertogh, Linda, van Rosmalen, Mandy, Jager, Agnes, de Man – van Ginkel, Janneke M., and Oldenmenger, Wendy H.
- Abstract
Cancer has a major impact on the individual patient and their family, especially children. However, little is known about the needs of adolescents (10–19 years) whose parent is diagnosed with cancer, especially breast cancer. Insights into psychosocial needs are important to develop appropriate guidance and support for these adolescents. The aim of this study is to explore the psychosocial needs of adolescents whose parent is diagnosed with breast cancer to improve the support for these adolescents. This is an exploratory, qualitative study. In-depth interviews were conducted, and an interview guide was designed with the following topics: experiences, needs, and support. Participants were selected purposively and approached via the parent(s) after consultation. Interviews were audiotaped, transcribed, and thematically analyzed by using the software program NVivo. Fourteen adolescents (12–19 years) were interviewed, which resulted in five themes: distraction, support, being able to talk about it, information, and continuing a normal life. Adolescents whose parent is diagnosed with breast cancer need the best possible preservation of their normal lives. It is important for them to be able to share their story and find support from someone close to them. The route to the adolescent is always through the parent. Healthcare professionals can discuss the well-being of the adolescent during regular consultation with the parent. If there are concerns, healthcare professionals can advise the parent about the possible needs of the adolescent and could coach the parent in supporting the adolescent to discuss their needs. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
10. A nationwide registry-based cohort study of the MammaPrint genomic risk classifier in invasive breast cancer.
- Author
-
Groenendijk, Floris H., Jager, Agnes, Cardoso, Fatima, and van Deurzen, Carolien H.M.
- Subjects
BREAST cancer ,TUMOR risk factors ,GENOMICS ,CANCER chemotherapy ,CANCER invasiveness ,HORMONE receptors - Abstract
Aim To evaluate the use of the MammaPrint assay, a 70-gene risk signature for early breast cancers, and to correlate genomic risk stratification with individual clinicopathological parameters and clinical risk as assessed by Adjuvant! Online. Methods A Dutch Pathology Registry (PALGA)-based cohort study consisting of 1916 patients for which 1946 MammaPrint assay results were synoptically reported from 2013 to 2016. We could retrospectively assess clinical risk for 1146 tumors (58.9%) using Adjuvant! Online (version 8.0 with HER2 status) and for 1155 tumors (59.4%) using PREDICT (version 2.0). Results Adjuvant! Online classified 718 tumors (62.7%) as clinical low risk and 428 tumors (37.3%) as clinical high risk. MammaPrint classified 1206 tumors (62.0%) as genomic low risk and 740 tumors (38.0%) as genomic high risk. Genomic risk stratification was significantly associated with histological subtype and grade (P < .001), hormonal receptor status (P < .001), presence of lymphovascular invasion (P = .001) and nodal status (P = .002), whereas no association was found with tumor size (P = .541). MammaPrint classified 52.6% of clinical high risk tumors (N = 428) as genomic low risk. This percentage was highest (67.3%) in clinical high risk ER-positive/HER2-negative grade 1–2 tumors (N = 282). Correlation between predicted overall survival benefit from adjuvant chemotherapy (PREDICT V2.0) and genomic risk distribution was almost linear. Conclusions This study showed that MammaPrint classified 52.6% of clinical high risk tumors as genomic low risk. In the Netherlands, 62.7% of the MammaPrint assays from 2013 to 2016 were performed on clinical low risk tumors, although recent International Guidelines recommend its use in clinical high and intermediate risk tumors. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
11. A Novel Less-invasive Approach for Axillary Staging After Neoadjuvant Chemotherapy in Patients With Axillary Node-positive Breast Cancer by Combining Radioactive Iodine Seed Localization in the Axilla With the Sentinel Node Procedure (RISAS): A Dutch Prospective Multicenter Validation Study.
- Author
-
van Nijnatten, Thiemo J. A., Simons, Janine M., Smidt, Marjolein L., van der Pol, Carmen C., van Diest, Paul J., Jager, Agnes, van Klaveren, David, Kam, Boen L.R., Lobbes, Marc B. I., de Boer, Maaike, Verhoef, Kees, Koppert, Linetta B., and Luiten, Ernest J. T.
- Published
- 2017
- Full Text
- View/download PDF
12. Low muscle attenuation is a prognostic factor for survival in metastatic breast cancer patients treated with first line palliative chemotherapy.
- Author
-
Rier, Hánah N., Jager, Agnes, Sleijfer, Stefan, van Rosmalen, Joost, Kock, Marc C.J.M., and Levin, Mark-David
- Subjects
MUSCLE mass ,BREAST cancer patients ,BREAST cancer prognosis ,CANCER chemotherapy ,SURVIVAL analysis (Biometry) - Abstract
Background Low muscle mass (LMM) and low muscle attenuation (LMA) reflect low muscle quantity and low muscle quality, respectively. Both are associated with a poor outcome in several types of solid malignancies. This study determined the association of skeletal muscle measures with overall survival (OS) and time to next treatment (TNT). Patients and methods A skeletal muscle index (SMI) in cm 2 /m 2 and muscle attenuation (MA) in Hounsfield units (HU) were measured using abdominal CT-images of 166 patients before start of first-line chemotherapy for metastatic breast cancer. Low muscle mass (SMI <41 cm 2 /m 2 ), sarcopenic obesity (LMM and BMI ≥30 kg/m 2 ) and low muscle attenuation (MA <41 HU and BMI <25 kg/m2 or MA <33 HU and BMI ≥25 kg/m2) were related to OS and TNT. Results The prevalence of LMM, sarcopenic obesity and LMA were 66.9%, 7.2% and 59.6% respectively. LMM and sarcopenic obesity showed no significant association with OS and TNT, whereas LMA was associated with both lower OS (HR 2.04, 95% CI 1.34–3.12, p = 0.001) and shorter TNT (HR 1.72, 95% CI 1.14–2.62, p = 0.010). Patients with LMA had a median OS and TNT of 15 and 8 months respectively, compared to 23 and 10 months in patients with normal MA. Conclusion LMA is a prognostic factor for OS and TNT in metastatic breast cancer patients receiving first-line palliative chemotherapy, whereas LMM and sarcopenic obesity are not. Further research is needed to establish what impact LMA should have in daily clinical practice. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
13. ESR1 mutations: Moving towards guiding treatment decision-making in metastatic breast cancer patients.
- Author
-
Angus, Lindsay, Beije, Nick, Jager, Agnes, Martens, John W.M., and Sleijfer, Stefan
- Abstract
Mutations in the gene coding for the estrogen receptor (ER), ESR1, have been associated with acquired endocrine resistance in patients with ER-positive metastatic breast cancer (MBC). Functional studies revealed that these ESR1 mutations lead to constitutive activity of the ER, meaning that the receptor is active in absence of its ligand estrogen, conferring resistance against several endocrine agents. While recent clinical studies reported that the occurrence of ESR1 mutations is rare in primary breast cancer tumors, these mutations are more frequently observed in metastatic tissue and circulating cell-free DNA of MBC patients pretreated with endocrine therapy. Given the assumed impact that the presence of ESR1 mutations has on outcome to endocrine therapy, assessing ESR1 mutations in MBC patients is likely to be of significant interest to further individualize treatment for MBC patients. Here, ESR1 mutation detection methods and the most relevant pre-clinical and clinical studies on ESR1 mutations regarding endocrine resistance are reviewed, with particular interest in the ultimate goal of guiding treatment decision-making based on ESR1 mutations. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
14. Individualization of tamoxifen therapy: Much more than just CYP2D6 genotyping.
- Author
-
Binkhorst, Lisette, Mathijssen, Ron H.J., Jager, Agnes, and van Gelder, Teun
- Abstract
Clinical response to tamoxifen varies widely among women treated with this drug for hormone receptor-positive breast cancer. The principal active metabolite – endoxifen – is generated through hepatic metabolism of tamoxifen, with key roles for cytochrome P450 (CYP) CYP2D6 and CYP3A. By influencing endoxifen formation, genetic variants of CYP2D6 may affect response to tamoxifen. After a decade of research, examining the effects of CYP2D6 genetic variants on tamoxifen efficacy, there is still no agreement on the clinical utility of CYP2D6 genotype as biomarker for the prediction of breast cancer outcome, because studies revealed conflicting results. However, tamoxifen metabolism is complex and involves several other drug-metabolizing enzymes. Genetic variants of other CYP enzymes, including CYP3A4 and CYP2C9/19 , as well as co-medication interfering with the metabolic activity of CYP2D6 and CYP3A4 have been shown to affect endoxifen concentrations and may also contribute to the variability in response to tamoxifen. Phenotyping strategies can predict endoxifen exposure more accurately than CYP2D6 genotype, but do not take into account all factors influencing endoxifen exposure. Therapeutic drug monitoring (TDM) is likely to be the optimal strategy for individualization of tamoxifen treatment. According to a growing amount of literature, endoxifen concentration seems to be a predictor of clinical outcome. The relationship between endoxifen levels and breast cancer outcomes has to be replicated and confirmed and the value of TDM should be evaluated in prospective clinical trials. Caution is advised regarding the concomitant use of medications which could interact with tamoxifen, including inhibitors and inducers of CYP enzymes. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
15. Overall survival in patients with a re-excision following breast conserving surgery compared to those without in a large population-based cohort.
- Author
-
Vos, Elvira L., Jager, Agnes, Verhoef, Cornelis, Voogd, Adri C., and Koppert, Linetta B.
- Subjects
- *
BREAST tumors , *PROBABILITY theory , *SURVIVAL , *RETROSPECTIVE studies , *DESCRIPTIVE statistics - Abstract
Aim To investigate the overall survival of invasive breast cancer patients with primary breast conserving surgery (BCS) followed by re-excision compared to those with primary BCS only. The Dutch re-excision indications are less stringent compared to other European and Northern American countries (Society of Surgical Oncology-American Society for Radiation Oncology (SSO/ASTRO) guideline). Methods Retrospective analyses in women <75 years with breast cancer stage pT1–T3 treated by BCS and radiotherapy between 1999 and 2012 from a population-based database. The national guideline recommends to reserve re-excision for invasive tumours showing ‘more than focally positive’ margin since 2002. Patients were divided into ‘primary BCS only’, ‘re-excision by BCS’, and ‘re-excision by mastectomy’. Multivariable Cox regression analysis was adjusted for patient and systemic treatment characteristics. Results A total of 11,695 patients were included of which 2156 (18.4%) underwent re-excision. Median time of follow-up was 61 months (interquartile range (IQR) 26–101). The 5-year overall survival rates in the ‘primary BCS only’, ‘re-excision by BCS’ and ‘re-excision by mastectomy’ group were 92%, 95% and 91%, respectively. The 10-year overall survival rates were 81%, 82% and 79%, respectively ( P = 0.20). After multivariable analyses no significant association was observed between use of and type of re-excision and overall survival. Conclusions The overall survival of breast cancer patients with a re-excision did not significantly differ from the survival of women who underwent primary BCS only. Advising re-excision only for those tumours showing ‘more than focally positive’ resection margin appears safe, supposing the long-term safety of the recent SSO/ASTRO guideline that more cautiously recommended re-excision for tumours showing ‘ink on tumour’. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
16. Circulating tumor cell enumeration by the CellSearch system: the clinician's guide to breast cancer treatment?
- Author
-
Beije, Nick, Jager, Agnes, and Sleijfer, Stefan
- Abstract
Circulating tumor cells (CTCs) are cancer cells that are present in the blood of patients with solid cancers and are shed from existing tumor lesions into the blood stream. The enumeration of CTCs has long been considered to hold great promise in guiding treatment decision-making in breast cancer patients. However, guidelines on how to use CTC enumeration in clinical decision-making in primary breast cancer and metastatic breast cancer are lacking. Here, we set out to review the most relevant literature to date, to ultimately come to general recommendations regarding the use of CTC enumeration in primary breast cancer and metastatic breast cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
17. Diagnostic and therapeutic ionizing radiation and the risk of a first and second primary breast cancer, with special attention for BRCA1 and BRCA2 mutation carriers: a critical review of the literature.
- Author
-
Drooger, Jan C, Hooning, Maartje J, Seynaeve, Caroline M, Baaijens, Margreet H A, Obdeijn, Inge Marie, Sleijfer, Stefan, and Jager, Agnes
- Abstract
Occurrence of breast cancer is a well-known long-term side effect of ionizing radiation (both diagnostic and therapeutic). The radiation-induced breast cancer risk increases with longer follow-up, higher radiation dose and younger age of exposure. The risk for breast cancer following irradiation for lymphomas is well known. Although data regarding the carcinogenic risk of adjuvant radiotherapy for a primary breast cancer are sparse, an increased risk is suggested with longer follow-up mainly when exposed at younger age. Particularly, patients with a BRCA1/2 mutation might be more sensitive for the deleterious effects of ionizing radiation due to an impaired capacity of repairing double strand DNA breaks. This might have consequences for the use of mammography in breast cancer screening, as well as the choice between breast conserving therapy including radiotherapy and mastectomy at primary breast cancer diagnosis in young BRCA1/2 mutation carriers. Good data regarding this topic, however, are scarce, mainly due to constraints in the design of performed studies. In this review, we will discuss the current literature on the association between ionizing radiation and developing breast cancer, with particular attention to patients with a BRCA1/2 mutation. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
18. Validity and utility of HER2/ERBB2 copy number variation assessed in liquid biopsies from breast cancer patients: A systematic review.
- Author
-
Verschoor, Noortje, Deger, Teoman, Jager, Agnes, Sleijfer, Stefan, Wilting, Saskia M., and Martens, John W.M.
- Abstract
Addition of HER2-targeted treatment in breast cancer is mainly determined by the HER2-receptor status of primary breast cancer tissue, since longitudinal sampling is burdensome and often not feasible. However, tumor heterogeneity and receptor conversion occur and may lead to improper diagnose as disease progresses. It is however possible that patients with their applied receptor status misjudged may benefit from HER2-targeted therapy. Liquid biopsies provide a useful source of information for receptor status and determine prognosis or evaluate therapy effectiveness. In this review, we give a comprehensive overview of current analytical and clinical validity and clinical utility of liquid biopsies for HER2 assessment. We systematically searched publications in Cochrane, Embase, PubMed and Google Scholar databases until April 2021 reporting on HER2-positivity in liquid biopsies and its concordance with tumor tissue, or on prognostic and/or predictive value of HER2-positivity in liquid biopsies. Applying our selection criteria, we identified 57 studies; 43 studies on circulating tumor cells, 13 studies on circulating tumor DNA and 1 study on extracellular vesicles. Most studies showed an association with outcome or treatment response, but used methods differed greatly, lacked a gold standard and evaluated patient groups differently hampering interpretation of results. We conclude that well-designed studies to determine assay validity and clinical validity and utility of HER2 assessment through liquid biopsies are currently lacking. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
19. Treatment-driven tumour heterogeneity and drug resistance: Lessons from solid tumours.
- Author
-
Crucitta, Stefania, Cucchiara, Federico, Mathijssen, Ron, Mateo, Joaquin, Jager, Agnes, Joosse, Arjen, Passaro, Antonio, Attili, Ilaria, Petrini, Iacopo, van Schaik, Ron, Danesi, Romano, and Del Re, Marzia
- Abstract
• Tumour heterogeneity is one of the major causes of drug resistance. • Therapy induces a selective pressure on resistant clones already present in tumour. • Mechanisms of resistance allow new targeted therapies approaches. Molecular heterogeneity characterizes tumours' evolution and adaptation and, because of its dynamics and continuous changes under external pressure, it is one of the major causes of drug resistance, contributing to therapy failure. Several studies reported evidence of molecular events occuring in individual tumours, including monoclonal or polyclonal resistance, and primary or secondary resistance mechanisms. While primary resistance is a phenomenon already present at the diagnosis of a tumor, the acquired one is strongly related to the selective pressure of treatments administered. Therefore, the pharmacological characteristics of a drug, including its potency, binding affinity and structure, largely influence the mechanism of resistance that will arise at the progression of the disease. As an example, the lung cancer experience clearly demonstrated that the highest is the potency of a drug on its target, the more are the possibilities that the mechanism of resistance will arise independently of the target itself. The present review is focused on tumour heterogeneity and its relation to resistance to targeted-therapy, based on treatment selective pressure across different tumour types, including lung, colorectal, prostate, breast cancer and melanoma. The mechanisms of resistance based on the drug potency and the selective pressure of treatments are discussed, leading to new drug developments or new therapeutic combinations. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
20. Do primary mammary osteosarcoma and chondrosarcoma exist? A review of a large multi-institutional series of malignant matrix-producing breast tumours.
- Author
-
Rakha, Emad A., Tan, Puay Hoon, Shaaban, Abeer, Tse, Gary M., Esteller, Fina Climent, van Deurzen, Carolien H.M., Purnell, Dave, Stotter, Anne, Chan, Timothy, Yamaguchi, Rin, Dodwell, David, Jager, Agnes, Soler, Maria Teresa, Juneinah, Enaam, Plaza, M.L., Hodi, Zsolt, McCulloch, Tom, Lee, Andrew H.S., and Ellis, Ian O.
- Subjects
BREAST tumors ,OSTEOSARCOMA ,CHONDROSARCOMA ,MULTIHOSPITAL systems ,LITERATURE reviews ,DUCTAL carcinoma ,FOLLOW-up studies (Medicine) - Abstract
Abstract: The existing literature describing the clinicopathological features and behaviour of matrix-producing (MP) malignant breast tumours presents conflicting results. As a consequence it remains uncertain whether these tumours should be treated as sarcoma and managed by a specialist sarcoma team or treated using the same principles as conventional ductal carcinoma, a dilemma that prompted this study. Improved understanding of the clinicopathological characteristics of primary mammary MP-sarcomas, namely osteosarcoma and chondrosarcoma, is required. Methods: In this large international multicenter series of malignant MP-tumours of the breast (no = 101) with follow-up information has been assessed and their outcome is compared to other subtypes of metaplastic breast carcinoma (MBC) (no = 253) and to grade, lymph node and hormone receptor-matched ductal breast carcinomas (no = 258). Results: The majority of MP-cancers were associated with epithelial features, which supports the concept that the majority of, if not almost all, primary MP breast sarcomas are of epithelial in origin (MBC). 21% showed nodal metastasis and the distribution of distant metastases resembled conventional mammary carcinoma. The prognosis of MP-MBC is comparable to matched ductal breast carcinoma and slightly better than other subtypes of MBC. Advanced stage (T3&T4) and development of recurrences were predictors of shorter survival in MP-MBC while grade and vascular invasion were not. Conclusion: Most malignant MP breast tumours are variants of MBC. MP-MBC with predominant mesenchymal components behaves similar to ductal carcinomas and although data on their response to systemic therapy is limited, there is no evidence that they should be managed differently from other forms of triple negative breast cancer. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
21. Corrigendum to "The impact of menstruation persistence or recovery after chemotherapy on survival in young patients with hormone receptor negative breast cancer" [Breast 52 (2020) 102–109].
- Author
-
van Barele, Mark, Heemskerk-Gerritsen, Bernadette A.M., van Doorn, Helena C., Schmidt, Marjanka K., Hooning, Maartje J., and Jager, Agnes
- Subjects
HORMONE receptors ,BREAST cancer ,MENSTRUATION ,BREAST ,CANCER chemotherapy - Published
- 2020
- Full Text
- View/download PDF
22. Ten-year follow-up of the observational RASTER study, prospective evaluation of the 70-gene signature in ER-positive, HER2-negative, node-negative, early breast cancer.
- Author
-
Vliek, Sonja B., Hilbers, Florentine S., Jager, Agnes, Retèl, Valesca P., Bueno de Mesquita, Jolien M., Drukker, Caroline A., Veltkamp, Sanne C., Zeillemaker, Anneke M., Rutgers, Emiel J., van Tinteren, Harm, van Harten, Wim H., van 't Veer, Laura J., van de Vijver, Marc J., and Linn, Sabine C.
- Subjects
- *
BREAST cancer prognosis , *BREAST tumor treatment , *ADJUVANT chemotherapy , *SCIENTIFIC observation , *CONFIDENCE intervals , *ONCOGENES , *GENETIC testing , *ESTROGEN receptors , *TREATMENT effectiveness , *GENE expression profiling , *DESCRIPTIVE statistics , *GENOMICS , *DECISION making in clinical medicine , *BREAST tumors , *LONGITUDINAL method - Abstract
Prognostic gene expression signatures can be used in combination with classical clinicopathological factors to guide adjuvant chemotherapy decisions in ER-positive, HER2-negative breast cancer. However, long-term outcome data after introduction of genomic testing in the treatment decision-making process are limited. In the prospective RASTER study, the tumours of 427 patients with cTanyN0M0 breast cancer were tested to assess the 70-gene signature (MammaPrint). The results were provided to their treating physician to be incorporated in the decision-making on adjuvant systemic therapy. Here, we report the long-term outcome of the 310 patients with ER-positive, HER2-negative tumours by clinical and genomic risk categories at a median follow-up of 10.3 years. Among the clinically high-risk patients, 45 (49%) were classified as genomically low risk. In this subgroup, at 10 years, distant recurrence free interval (DRFI) was similar between patients treated with (95.7% [95% CI 87.7–100]) and without (95.5% [95% CI 87.1–100]) chemotherapy. Within the group of clinically low-risk patients, 56 (26%) were classified as genomically high risk. Within the clinically low-risk group, beyond 5 years, a difference emerged between the genomically high- and low-risk subgroup resulting in a 10-year DRFI of 84.3% (95% CI 74.8–95.0) and 93.4% (95% CI 89.5–97.5), respectively. Interestingly, genomic ultralow-risk patients have a 10-year DRFI of 96.7% (95% CI 90.5–100), largely (79%) without systemic therapy. These data confirm that clinically high-risk, genomically low-risk tumours have an excellent outcome in the real-world setting of shared decision-making. Together with the updated results of the MINDACT trial, these data support the use of the MammaPrint, in ER-positive, HER2-negative, node-negative, clinically high-risk breast cancer patients. ISRCTN71917916 • Clinical high-risk, genomic low-risk tumours have similar DRFI with or without chemo. • Genomic ultralow-risk tumours have a good outcome largely without systemic therapy. • 10-year DRFI in clinical low-risk, genomic high-risk tumours suggest undertreatment. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
23. Erratum to "Prognostic factors in patients with oligometastatic breast cancer - A systematic review". [Cancer treatment Rev. 91 (2020) 102114].
- Author
-
van Ommen – Nijhof, Annemiek, Steenbruggen, Tessa G., Schats, Winnie, Wiersma, Terry, Horlings, Hugo M., Mann, Ritse, Koppert, Linetta, van Werkhoven, Erik, Sonke, Gabe S., Jager, Agnes, and van Ommen-Nijhof, Annemiek
- Published
- 2021
- Full Text
- View/download PDF
24. Prognostic factors in patients with oligometastatic breast cancer - A systematic review.
- Author
-
van Ommen – Nijhof, Annemiek, Steenbruggen, Tessa G, Schats, Winnie, Wiersma, Terry, Horlings, Hugo M., Mann, Ritse, Koppert, Linetta, van Werkhoven, Erik, Sonke, Gabe S., Jager, Agnes, and van Ommen-Nijhof, Annemiek
- Abstract
Aim: Oligometastatic breast cancer (OMBC) is a disease-entity with potential for long-term remission in selected patients. Those with truly limited metastatic load (rather than occult widespread metastatic disease) may benefit from multimodality treatment including local ablative therapy of distant metastases. In this systematic review, we studied factors associated with long-term survival in patients with OMBC.Methods: Eligible studies included patients with OMBC who received a combination of local and systemic therapy as multimodal approach and reported overall survival (OS) or progression-free survival (PFS), or both. The Quality in Prognosis Studies (QUIPS) tool was used to assess the quality of each included study. Independent prognostic factors for OS and/or PFS are summarized.Results: Of 1271 screened abstracts, 317 papers were full-text screened and twenty studies were included. Eleven of twenty studies were classified as acceptable quality. Definition of OMBC varied between studies and mostly incorporated the number and/or location of metastases. The 5-year OS ranged between 30 and 79% and 5-year PFS ranged between 25 and 57%. Twelve studies evaluated prognostic factors for OS and/or PFS in multivariable models. A solitary metastasis, >24 months interval between primary tumor and OMBC, no or limited involved axillary lymph nodes at primary diagnosis, and hormone-receptor positivity were associated with better outcome. HER2-positivity was associated with worse outcome, but only few patients received anti-HER2 therapy.Conclusions: OMBC patients with a solitary distant metastasis and >24 months disease-free interval have the best OS and may be optimal candidates to consider a multidisciplinary approach. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
25. From Multiple Quality Indicators of Breast Cancer Care Toward Hospital Variation of a Summary Measure.
- Author
-
Vos, Elvira L., Koppert, Linetta B., Jager, Agnes, Vrancken Peeters, Marie-Jeanne T.F.D., Siesling, Sabine, and Lingsma, Hester F.
- Subjects
- *
BREAST cancer , *HOSPITAL care , *TEST validity , *HOSPITAL central service departments , *CANCER patients , *BREAST tumor treatment , *MEDICAL quality control , *HOSPITALS , *RESEARCH , *KEY performance indicators (Management) , *RESEARCH methodology , *EVALUATION research , *MEDICAL cooperation , *RISK assessment , *BENCHMARKING (Management) , *COMPARATIVE studies , *CLINICAL medicine , *BREAST tumors - Abstract
Objectives: To improve quality in breast cancer care, large numbers of quality indicators are collected per hospital, but benchmarking remains complex. We aimed to assess the validity of indicators, develop a textbook outcome summary measure, and compare case-mix adjusted hospital performance.Methods: From a nationwide population-based registry, all 79 690 nonmetastatic breast cancer patients surgically treated between 2011 and 2016 in 91 hospitals in The Netherlands were included. Twenty-one indicators were calculated and their construct validity tested by Spearman's rho. Between-hospital variation was expressed by interquartile range (IQR), and all valid indicators were included in the summary measure. Standardized scores (observed/expected based on case mix) were calculated as above (>100) or below (<100) expected. The textbook outcome was presented as a continuous and all-or-none score.Results: The size of between-hospital variation varied between indicators. Sixteen (76%) of 21 quality indicators showed construct validity, and 13 were included in the summary measure after excluding redundant indicators that showed collinearity with others owing to strong construct validity. The median all-or-none textbook outcome score was 49% (IQR 42%-54%) before and 49% (IQR 48%-51%) after case-mix adjustment. From the total of 91 hospitals, 3 hospitals were positive (3%) and 9 (10%) were negative outliers.Conclusions: The textbook outcome summary measure showed discriminative ability when hospital performance was presented as an all-or-none score. Although indicator scores and outlier hospitals should always be interpreted cautiously, the summary measure presented here has the potential to improve Dutch breast cancer quality indicator efforts and could be implemented to further test its validity, feasibility, and usefulness. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
26. Effect of Case-Mix and Random Variation on Breast Cancer Care Quality Indicators and Their Rankability.
- Author
-
Vos, Elvira L., Lingsma, Hester F., Jager, Agnes, Schreuder, Kay, Spronk, Pauline, Vrancken Peeters, Marie-Jeanne T.F.D., Siesling, Sabine, and Koppert, Linetta B.
- Subjects
- *
HOSPITAL quality control , *HOSPITAL care quality , *RATINGS of hospitals , *BREAST cancer , *LUMPECTOMY , *MAGNETIC resonance imaging , *TEST validity , *BREAST tumor treatment , *HOSPITALS , *DATABASES , *RESEARCH , *KEY performance indicators (Management) , *RESEARCH methodology , *EVALUATION research , *MEDICAL cooperation , *BENCHMARKING (Management) , *COMPARATIVE studies , *CLINICAL medicine , *QUALITY assurance , *BREAST tumors , *LONGITUDINAL method ,RESEARCH evaluation - Abstract
Objectives: Hospital comparisons to improve quality of care require valid and reliable quality indicators. We aimed to test the validity and reliability of 6 breast cancer indicators by quantifying the influence of case-mix and random variation.Methods: The nationwide population-based database included 79 690 patients with breast cancer from 91 Dutch hospitals between 2011 and 2016. The indicator-scores calculated were: (1) irradical breast-conserving surgery (BCS) for invasive disease, (2) irradical BCS for ductal carcinoma-in-situ, (3) breast contour-preserving treatment, (4) magnetic resonance imaging (MRI) before neo-adjuvant chemotherapy, (5) radiotherapy for locally advanced disease, and (6) surgery within 5 weeks from diagnosis. Case-mix and random variation adjustments were performed by multivariable fixed and random effect logistic regression models. Rankability quantified the between-hospital variation, representing unexplained differences that might be the result of the level of quality of care, as low (<50%), moderate (50%-75%), or high (>75%).Results: All of the indicators showed between-hospital variation with wide (interquartile) ranges. Case-mix adjustment reduced variation in indicators 1 and 3 to 5. Random variation adjustment (further) reduced the variation for all indicators. Case-mix and random variation adjustments influenced the indicator-scores of individual hospitals and their ranking. Rankability was poor for indicator 1, 2, and 5, and moderate for 3, 4, and 6.Conclusions: The 6 indicators lacked validity and/or reliability to a certain extent. Although measuring quality indicators may stimulate quality improvement in general, comparisons and judgments of individual hospital performance should be made with caution if based on indicators that have not been tested or adjusted for validity and reliability, especially in benchmarking. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
27. A review of trials investigating ctDNA-guided adjuvant treatment of solid tumors: The importance of trial design.
- Author
-
Verschoor, Noortje, Bos, Manouk K., Oomen-de Hoop, Esther, Martens, John W.M., Sleijfer, Stefan, Jager, Agnes, and Beije, Nick
- Subjects
- *
CLINICAL trials , *BREAST tumors , *DRUG administration , *TUMOR markers , *COLORECTAL cancer , *PATIENT care , *TREATMENT effectiveness , *DNA , *ADJUVANT chemotherapy , *NUCLEIC acids , *LUNG tumors , *TUMORS , *EXTRACELLULAR space , *TUMOR classification , *MEDICAL ethics , *BLOOD - Abstract
Circulating tumor DNA (ctDNA) holds promise as a biomarker for guiding adjuvant treatment decisions in solid tumors. This review systematically assembles ongoing and published trials investigating ctDNA-directed adjuvant treatment strategies. A total of 57 phase II/III trials focusing on ctDNA in minimal residual disease (MRD) detection were identified, with a notable increase in initiation over recent years. Most trials target stage II or III colon/colorectal cancer, followed by breast cancer and non-small cell lung cancer. Trial methodologies vary, with some randomizing ctDNA-positive patients between standard-of-care (SoC) treatment and intensified regimens, while others aim to de-escalate therapy in ctDNA-negative patients. Challenges in trial design include the need for randomized controlled trials to establish clinical utility for ctDNA, ensuring adherence to standard treatment in control arms, and addressing the ethical dilemma of withholding treatment in high-risk ctDNA-positive patients. Longitudinal ctDNA surveillance emerges as a strategy to improve sensitivity for recurrence, particularly in less proliferative tumor types. However, ctDNA as longitudinal marker is often not validated yet. Ultimately, designing effective ctDNA interventional trials requires careful consideration of feasibility, meaningful outcomes, and potential impact on patient care. • ctDNA are promising MRD biomarkers for solid tumors. • 57 phase II/III trials are running in the adjuvant treatment setting, mostly in colorectal cancer. • Most trials focus on escalating treatment in patients with detected ctDNA. • Challenges in trial design include ethical concerns and applicability of outcomes. • We propose potential trial designs to resolve some of the issues. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
28. Serum homocysteine level and protein intake are related to risk of microalbuminuria: The Hoorn Study.
- Author
-
Hoogeveen, Ellen K., Kostense, Pieter J., Jager, Agnes, Heine, Robert J., Jakobs, Cornelis, Bouter, Lex M., Donker, J.M., and Stehouwer, Coen D.A.
- Subjects
- *
HOMOCYSTEINE , *PROTEINS , *CREATININE , *MEASUREMENT - Abstract
Examines the relationship between serum homocysteine level, protein intake and microalbuminuria in Amsterdam, Netherlands. Impairment of glucose tolerance; Measurement of urinary creatinine; Ranges of daily protein intake.
- Published
- 1998
- Full Text
- View/download PDF
29. The interplay between tamoxifen and endoxifen plasma concentrations and coagulation parameters in patients with primary breast cancer.
- Author
-
Buijs, Sanne M., van Dorst, Daan C.H., Kruip, Marieke J.H.A., van den Akker, Rob F.P., Cheung, Ka L., Porrazzo, Robert, Oomen-de Hoop, Esther, Jager, Agnes, Koolen, Stijn L.W., Versmissen, Jorie, Jan Danser, A.H., Versteeg, Henri H., Bos, Mettine H.A., and Mathijssen, Ron H.J.
- Subjects
- *
CANCER patients , *TAMOXIFEN , *BLOOD coagulation , *PROTEIN C , *THROMBOEMBOLISM - Abstract
Tamoxifen is an effective treatment for primary breast cancer but increases the risk for venous thromboembolism. Tamoxifen decreases anticoagulant proteins, including antithrombin (AT), protein C (PC) and tissue factor (TF) pathway inhibitor, and enhances thrombin generation (TG). However, the relation between plasma concentrations of both tamoxifen and its active metabolite endoxifen and coagulation remains unknown. Tamoxifen and endoxifen were measured in 141 patients from the prospective open-label intervention TOTAM-study after 3 months (m) and 6 m of tamoxifen treatment. Levels of AT and PC, the procoagulant TF, and TG parameters were determined at both timepoints if samples were available (n = 53–135 per analysis). Levels of coagulation proteins and TG parameters were correlated and compared between: 1) quartiles of tamoxifen and endoxifen levels, and 2) 3 m and 6 m of treatment. At 3 m, levels of AT, PC, TF and TG parameters were not associated with tamoxifen nor endoxifen levels. At 6 m, median TF levels were lower in patients in the 3rd (56.6 [33] pg/mL), and 4th (50.1 [19] pg/mL) endoxifen quartiles compared to the 1st (lowest) quartile (76 [69] pg/mL) (P= 0.027 and P= 0.018, respectively), but no differences in anticoagulant proteins or TG parameters were observed. An increase in circulating TF levels (3 m: 46.0 [15] versus 6 m: 54.4 [39] pg/mL, P < 0.001) and TG parameters was observed at the 6 m treatment timepoint, while AT and PC levels remained stable. Our results indicate that higher tamoxifen and endoxifen levels are not correlated with an increased procoagulant state, suggesting tamoxifen dose escalation does not further promote hypercoagulability. [Display omitted] • Patients who receive tamoxifen have increased risk of venous thromboembolism (VTE). • Higher tamoxifen or endoxifen levels do not correlate with an enhanced procoagulant state. • This points towards no further increase in VTE risk upon tamoxifen dose escalation. • Tamoxifen may increase tissue factor levels over time which requires further study. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
30. Toward model-informed precision dosing for tamoxifen: A population-pharmacokinetic model with a continuous CYP2D6 activity scale.
- Author
-
Agema, Bram C., Buijs, Sanne M., Sassen, Sebastiaan D.T., Mürdter, Thomas E., Schwab, Mathias, Koch, Birgit C.P., Jager, Agnes, van Schaik, Ron H.N., Mathijssen, Ron H.J., and Koolen, Stijn L.W.
- Subjects
- *
CYTOCHROME P-450 CYP2D6 , *TAMOXIFEN , *ADJUVANT treatment of cancer , *DRUG monitoring - Abstract
Tamoxifen is important in the adjuvant treatment of breast cancer. A plasma concentration of the active metabolite endoxifen of > 16 nM is associated with a lower risk of breast cancer-recurrence. Since inter-individual variability is high and > 20 % of patients do not reach endoxifen levels > 16 nM with the standard dose tamoxifen, therapeutic drug monitoring is advised. However, ideally, the correct tamoxifen dose should be known prior to start of therapy. Our aim is to develop a population pharmacokinetic (POP-PK) model incorporating a continuous CYP2D6 activity scale to support model informed precision dosing (MIPD) of tamoxifen to determine the optimal tamoxifen starting dose. Data from eight different clinical studies were pooled (539 patients, 3661 samples) and used to develop a POP-PK model. In this model, CYP2D6 activity per allele was estimated on a continuous scale. After inclusion of covariates, the model was subsequently validated using an independent external dataset (378 patients). Thereafter, dosing cut-off values for MIPD were determined. A joint tamoxifen/endoxifen POP-PK model was developed describing the endoxifen formation rate. Using a continuous CYP2D6 activity scale, variability in predicting endoxifen levels was decreased by 37 % compared to using standard CYP2D6 genotype predicted phenotyping. After external validation and determination of dosing cut-off points, MIPD could reduce the proportion of patients with subtherapeutic endoxifen levels at from 22.1 % toward 4.8 %. Implementing MIPD from the start of tamoxifen treatment with this POP-PK model can reduce the proportion of patients with subtherapeutic endoxifen levels at steady-state to less than 5 %. [Display omitted] • Continuous expression of CYP2D6 activity based on genotype is feasible. • A model-informed dosing strategy for tamoxifen therapy was developed. • The proportion of patients with subtherapeutic levels can be reduced from 21 % to 5 %. • This is the first clinical application for model-informed precision dosing in oncology. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
31. Health-related quality of life and productivity costs in breast cancer patients treated with tamoxifen in the Netherlands.
- Author
-
Kleijburg, Anne, Braal, C. Louwrens, Westenberg, Justin D., Jager, Agnes, Koolen, Stijn L.W., Mathijssen, Ron H.J., Uyl-de Groot, Carin A., Wetzelaer, Pim, and Penton, Hannah
- Subjects
- *
QUALITY of life , *CANCER patients , *BREAST cancer , *TAMOXIFEN , *ECONOMIC models - Abstract
The aim of this study was to describe health-related quality of life (HRQoL) and productivity in Dutch breast cancer patients treated with tamoxifen in an adjuvant setting. Patients who started treatment with a standard dose of tamoxifen and who gave written informed consent, were eligible for participation in this trial. A total of 145 patients were asked to complete a survey at 3 months (T1) and 6 months (T2) after initiation of tamoxifen. HRQoL was measured by the EQ-5D-5L and the FACT-B questionnaire, and productivity by using the iMTA Productivity Costs Questionnaire. At 3 months 137 (95%) and at 6 months 133 (92%) patients responded to the surveys. EQ-5D-5 L utility values for T1 and T2 were 0.81 ± 0.17 and 0.81 ± 0.18, respectively. FACT-B scores for T1 and T2 were 109 ± 17.9 and 108 ± 20.0, respectively. No differences in both EQ-5D-5 L utility and FACT-B scores were found between T1 and T2 (p > 0.05). Age and employment status were statistically significantly associated with FACT-B scores (p = 0.04 and p = 0.03, respectively), indicating that younger and unemployed respondents had lower FACT-B scores. Importantly, both short-term and long-term productivity improved during the first six months of tamoxifen treatment (p < 0.05). Here, short-term productivity losses (consisting of absenteeism, presenteeism and unpaid work) for T1 and T2 were estimated at € 855,- and € 396,-, respectively. Long-term productivity losses (consisting of absenteeism) for T1 and T2 were estimated at € 2876,- and € 1104,-, respectively. In conclusion, this study presents HRQoL scores using different instruments and detailed loss of productivity estimates for breast cancer patients treated with adjuvant endocrine therapy. The results presented here can be used to inform input parameters in health economic evaluations of interventions for patients with breast cancer in the Netherlands and other Western countries and ultimately support decision making. [Display omitted] • Health economic models require input parameters to describe the patient population evaluated. • The EQ-5D-5 L and FACT-B and productivity were assessed in tamoxifen-treated breast cancer patients. • Younger and employed patients had overall better quality of life. • Productivity of patients improved during the first 6 months of treatment with tamoxifen. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
32. Prognostic Impact of HER2 and ER Status of Circulating Tumor Cells in Metastatic Breast Cancer Patients with a HER2-Negative Primary Tumor.
- Author
-
Beije, Nick, Onstenk, Wendy, Kraan, Jaco, Sieuwerts, Anieta M., Hamberg, Paul, Dirix, Luc Y., Brouwer, Anja, de Jongh, Felix E., Jager, Agnes, Seynaeve, Caroline M., Ngoc M. Van, Foekens, John A., Martens, John W. M., and Sleijfer, Stefan
- Subjects
- *
BREAST cancer treatment , *HER2 protein , *ESTROGEN receptors , *HORMONE therapy , *PROGRESSION-free survival , *DISEASE prevalence , *CANCER chemotherapy - Abstract
BACKGROUND: Preclinical and clinical studies have reported that human epidermal growth factor receptor 2 (HER2) overexpression yields resistance to endocrine therapies. Here the prevalence and prognostic impact of HER2-positive circulating tumor cells (CTCs) were investigated retrospectively in metastatic breast cancer (MBC) patients with a HER2-negative primary tumor receiving endocrine therapy. Additionally, the prevalence and prognostic significance of HER2-positive CTCs were explored in a chemotherapy cohort, as well as the prognostic impact of the estrogen receptor (ER) CTC status in both cohorts. METHODS: Included were MBC patients with a HER2-negative primary tumor, with ≥1 detectable CTC, starting a new line of treatment. CTCs were enumerated using the CellSearch system, characterized for HER2 with the CellSearch anti-HER2 phenotyping reagent, and characterized for ER mRNA expression. Primary end point was progression-free rate after 6 months (PFR6months) of endocrine treatment in HER2-positive versus HER2-negative CTC patients. RESULTS: HER2-positive CTCs were present in 29% of all patients. In the endocrine cohort (n = 72), the PFR6months was 53% for HER2-positive versus 68% for HER2-negative CTC patients (P = .23). In the chemotherapy cohort (n = 82), no prognostic value of HER2-positive CTCs on PFR6months was observed either. Discordances in ER status between the primary tumor and CTCs occurred in 25% of all patients but had no prognostic value in exploratory survival analyses. CONCLUSION: Discordances regarding HER2 status and ER status between CTCs and the primary tumor occurred frequently but had no prognostic impact in our MBC patient cohorts. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
33. Gene expression profiles of circulating tumor cells versus primary tumors in metastatic breast cancer.
- Author
-
Onstenk, Wendy, Sieuwerts, Anieta M., Weekhout, Marleen, Mostert, Bianca, Reijm, Esther A., van Deurzen, Carolien H.M., Bolt-de Vries, Joan B., Peeters, Dieter J., Hamberg, Paul, Seynaeve, Caroline, Jager, Agnes, de Jongh, Felix E., Smid, Marcel, Dirix, Luc Y., Kehrer, Diederik F.S., van Galen, Anne, Ramirez-Moreno, Raquel, Kraan, Jaco, Van, Mai, and Gratama, Jan W.
- Subjects
- *
BREAST cancer treatment , *BREAST cancer patients , *GENE expression , *BIOPSY , *STATISTICAL correlation , *METASTASIS - Abstract
Before using circulating tumor cells (CTCs) as liquid biopsy, insight into molecular discrepancies between CTCs and primary tumors is essential. We characterized CellSearch-enriched CTCs from 62 metastatic breast cancer (MBC) patients with ≥5 CTCs starting first-line systemic treatment. Expression levels of 35 tumor-associated, CTC-specific genes, including ESR1 , coding for the estrogen receptor (ER), were measured by reverse transcription quantitative polymerase chain reaction and correlated to corresponding primary tumors. In 30 patients (48%), gene expression profiles of 35 genes were discrepant between CTCs and the primary tumor, but this had no prognostic consequences. In 15 patients (24%), the expression of ER was discrepant. Patients with ER-negative primary tumors and ER-positive CTCs had a longer median TTS compared to those with concordantly ER-negative CTCs (8.5 versus 2.1 months, P = 0.05). From seven patients, an axillary lymph node metastasis was available. In two patients, the CTC profiles better resembled the lymph node metastasis than the primary tumor. Our findings suggest that molecular discordances between CTCs and primary tumors frequently occur, but that this bears no prognostic consequences. Alterations in ER-status between primary tumors and CTCs might have prognostic implications. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
34. Denosumab in breast cancer treatment.
- Author
-
Drooger, Jan C., van der Padt, Annemieke, Sleijfer, Stefan, and Jager, Agnes
- Subjects
- *
BREAST cancer treatment , *MONOCLONAL antibodies , *BONE metastasis , *DRUG receptors , *NF-kappa B , *BONE density , *AROMATASE inhibitors - Abstract
Abstract: The bone is the most common site to which breast cancer metastasises. Recently, denosumab, a fully human monoclonal antibody that binds to receptor activator of nuclear factor kappa-B ligand (RANKL) has been developed as a new targeted bone therapy. In a large randomized phase III study with a head-to-head comparison of denosumab to zoledronic acid in patients with bone metastases of breast cancer, denosumab significantly delayed the time to first skeletal related event. In the adjuvant setting denosumab significantly increased bone mineral density compared to placebo in a phase III study in patients treated with aromatase inhibitors. Preclinical data suggest an effect of denosumab on tumour growth and even on carcinogenesis. This review describes the current indications for denosumab in the various settings of breast cancer treatment, with special attention for efficacy, short and long term toxicity and other relevant issues for clinical practice. Furthermore possible and necessary future research questions are proposed. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.